Vaccine May Provide Some Protection From Hepatitis E

Share this content:
Vaccine May Provide Some Protection From Hepatitis E
Vaccine May Provide Some Protection From Hepatitis E

THURSDAY, March 5, 2015 (HealthDay News) -- A vaccine for hepatitis E provides protection from the virus for at least 4.5 years, according to new research. The report was published in the March 5 issue of the New England Journal of Medicine.

Ning-Shao Xia, M.D., a professor in the department of biology at Xiamen University in China, and colleagues randomly assigned 56,302 healthy adults, aged 16 to 65, to get three shots of the hepatitis E vaccine. At the same time, 56,302 additional adults were injected with the hepatitis B vaccine (control group).

During the 4.5 years of follow-up, 60 people developed hepatitis E. Seven were among those who received the hepatitis E vaccine, and 53 cases developed in those given the hepatitis B vaccine, the researchers found. Eight-seven percent of those who received three doses of the hepatitis E vaccine maintained antibodies against the virus for at least 4.5 years, the study authors said.

Hepatitis E is spread in areas where sanitation is poor. "Many people get sick from this virus, but only 1 to 3 percent die from it, except [among] pregnant women," John Ward, M.D., the director of the division of viral hepatitis at the U.S. Centers for Disease Control and Prevention in Atlanta and coauthor of an accompanying journal editorial, told HealthDay. "Pregnant women have about a one in five chance of dying. There is no treatment for hepatitis E."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »